Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells

Blood

Volumn 106, Issue 9, 2005, Pages 3062-3067

  Xue, Shao An ^b   Gao, Liquan ^b   Hart, Daniel ^b   Gillmore, Roopinder ^b   Qasim, Waseem ^b   Thrasher, Adrian ^b   Apperley, Jane ^b   Engels, Boris ^b   Uckert, Wolfgang ^b   Morris, Emma ^b   Stauss, Hans ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; WT1 PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; DNA MODIFICATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 27644566777     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-01-0146     Document Type: Article

References (44)

1. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
2. Horowitz MM, Gale RP, Sondel PM, et al. Graftversus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
3. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stemcell transplantation. N Engl J Med. 2000;343:750-758.
4. Hughes TP, Economou K, Mackinnon S, et al. Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. Br J Haematol. 1989;73:462-467.
5. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725-729.
6. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-384.
7. Gotter J, Kyewski B. Regulating self-tolerance by deregulating gene expression. Curr Opin Immunol. 2004;16:741-745.
8. Goulmy E. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer J. 2004;10:1-7.
9. Warren EH, Gavin M, Greenberg PD, Riddell SR. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol. 1998;5:429-433.
10. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A. 2003;100:2742-2747.
11. Stauss HJ. Immunotherapy with CTLs restricted by nonself MHC. Immunol Today. 1999;20:180-183.
12. Rotzschke O, Falk K, Faath S, Rammensee HG. On the nature of peptides involved in T cell alloreactivity. J Exp Med. 1991;174:1059-1071.
13. Aosai F, Ohlen C, Ljunggren HG, et al. Different types of allospecific CTL clones identified by their ability to recognize peptide loading-defective target cells. Eur J Immunol. 1991;21:2767-2774.
14. Matzinger P, Zamoyska R, Waldmann H. Self tolerance is H-2-restricted. Nature. 1984;308:738-741.
15. Rammensee HG, Bevan MJ. Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature. 1984;308:741-744.
16. Sadovnikova E, Jopling LA, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by nonself HLA class I molecules. Eur J Immunol. 1998;28:193-200.
17. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-2203.
18. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2001;2:962-970.
19. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999;90:194-204.
20. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89:1405-1412.
21. Bellantuono I, Gao L, Parry S, et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood. 2002;100:3835-3837.
22. Gao L, Xue SA, Hasserjian R, et al. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation. 2003;75:1429-1436.
23. DeMars R, Chang CC, Shaw S, Reitnauer PJ, Sondel PM. Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells, I: reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum Immunol. 1984;11:77-97.
24. Pegoraro L, Matera L, Ritz J, Levis A, Palumbo A, Biagini G. Establishment of a Ph1-positive human cell line (BV173). J Natl Cancer Inst. 1983;70:447-453.
25. Findley HW Jr, Cooper MD, Kim TH, Alvarado C, Ragab AH. Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes. Blood. 1982;60:1305-1309.
26. Xue SA, Lu QL, Poulsom R, Karran L, Jones MD, Griffin BE. Expression of two related viral early genes in Epstein-Barr virus-associated tumors. J Virol. 2000;74:2793-2803.
27. Moonka D, Loh EY. A consensus primer to amplify both alpha and beta chains of the human T cell receptor. J Immunol Methods. 1994;169:41-51.
28. Engels B, Cam H, Schuler T, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther. 2003;14:1155-1168.
29. Bendle GM, Holler A, Pang LK, et al. Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Res. 2004;64:8052-8056.
30. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001;20:1897-1909.
31. Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol. 1997;25:312-320.
32. Menssen HD, Renkl HJ, Entezami M, Thiel E. Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood. 1997;89:3486-3487.
33. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999;163:507-513.
34. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol. 2000;74:8207-8212.
35. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN. Immunotherapy through TCR gene transfer. Nat Immunol. 2001;2:957-961.
36. Schaft N, Willemsen RA, de Vries J, et al. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol. 2003;170:2186-2194.
37. Orentas RJ, Bircher LA, Roskopf S. Retroviral transfer of T-cell receptor genes produces cells with a broad range of lytic activity. Scand J Immunol. 2003;58:33-42.
38. Morgan RA, Dudley ME, Yu YY, et al. High effi-ciency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol. 2003;171:3287-3295.
39. Fujio K, Misaki Y, Setoguchi K, et al. Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J Immunol. 2000;165:528-532.
40. Heemskerk MH, Hoogeboom M, de Paus RA, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood. 2003;102:3530-3540.
41. Tahara H, Fujio K, Araki Y, et al. Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte. J Immunol. 2003;171:2154-2160.
42. Heemskerk MH, Hoogeboom M, Hagedoorn R, Kester MG, Willemze R, Falkenburg JH. Reprogramming of virus-specific T cells into leukemiareactive T cells using T cell receptor gene transfer. J Exp Med. 2004;199:885-894.
43. Chamoto K, Tsuji T, Funamoto H, et al. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced Thelper type 1 cells. Cancer Res. 2004;64:386-390.
44. Loeb DM, Evron E, Patel CB, et al. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res. 2001;61:921-925.